ASCO Congress 2018: melanoma treatment

The 2018 ASCO Annual Meeting provided a closer look on the details of studies already presented. In melanoma, the interest was on neoadjuvant treatment options with high pathological response rates as well as updates on large phase III studies in stage IV disease. Further new targets were discussed...

Descripción completa

Detalles Bibliográficos
Autor principal: Richtig, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280769/
https://www.ncbi.nlm.nih.gov/pubmed/30595751
http://dx.doi.org/10.1007/s12254-018-0455-4
_version_ 1783378733815562240
author Richtig, Erika
author_facet Richtig, Erika
author_sort Richtig, Erika
collection PubMed
description The 2018 ASCO Annual Meeting provided a closer look on the details of studies already presented. In melanoma, the interest was on neoadjuvant treatment options with high pathological response rates as well as updates on large phase III studies in stage IV disease. Further new targets were discussed focusing on additional drugs to a PD-1 backbone treatment. Another focus was on Merkel cell carcinoma and basal cell carcinomas, giving new data on PD-1 antibody treatments as well as on vismodegib as neoadjuvant therapy.
format Online
Article
Text
id pubmed-6280769
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-62807692018-12-26 ASCO Congress 2018: melanoma treatment Richtig, Erika Memo Short Review The 2018 ASCO Annual Meeting provided a closer look on the details of studies already presented. In melanoma, the interest was on neoadjuvant treatment options with high pathological response rates as well as updates on large phase III studies in stage IV disease. Further new targets were discussed focusing on additional drugs to a PD-1 backbone treatment. Another focus was on Merkel cell carcinoma and basal cell carcinomas, giving new data on PD-1 antibody treatments as well as on vismodegib as neoadjuvant therapy. Springer Vienna 2018-11-20 2018 /pmc/articles/PMC6280769/ /pubmed/30595751 http://dx.doi.org/10.1007/s12254-018-0455-4 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Review
Richtig, Erika
ASCO Congress 2018: melanoma treatment
title ASCO Congress 2018: melanoma treatment
title_full ASCO Congress 2018: melanoma treatment
title_fullStr ASCO Congress 2018: melanoma treatment
title_full_unstemmed ASCO Congress 2018: melanoma treatment
title_short ASCO Congress 2018: melanoma treatment
title_sort asco congress 2018: melanoma treatment
topic Short Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280769/
https://www.ncbi.nlm.nih.gov/pubmed/30595751
http://dx.doi.org/10.1007/s12254-018-0455-4
work_keys_str_mv AT richtigerika ascocongress2018melanomatreatment

Ejemplares similares